• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

    41.96 +0.74 (+1.80%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roche Holding AG Basel American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
    Might the tariff risk for pharmaceutical stocks be less than you think? 
    Via The Motley Fool
    Topics Government World Trade
    Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
    Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims for European launch in 2025 
    Via Benzinga
    Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
    Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
    Via Benzinga
    Topics Government World Trade
    Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
    Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook. 
    Via Benzinga
    Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
    From Genentech
    Via Business Wire
    Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
    Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis. 
    Via Benzinga
    IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
    The companies both have drugs that treat relapsing forms of multiple sclerosis. 
    Via Investor's Business Daily
    Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
    From Genentech
    Via Business Wire
    Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
    UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
    Via Benzinga
    Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
    Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option. 
    Via Benzinga
    The Best Vanguard ETF to Invest $1,000 in Right Now
    Via The Motley Fool
    Topics ETFs
    Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
    Ignore the noise in GLP-1 stocks. Find the best value instead. 
    Via The Motley Fool
    Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
    The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
    Via Investor's Business Daily
    Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
    Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights. 
    Via Benzinga
    FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
    From Genentech
    Via Business Wire
    FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
    From Genentech
    Via Business Wire
    Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
    Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events. 
    Via Benzinga
    Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
    From Genentech
    Via Business Wire
    NovoCure Q4 EPS Misses, Revenue Matches
    NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
    Via The Motley Fool
    Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
    Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
    Via MarketBeat
    FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
    From Genentech
    Via Business Wire
    New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
    From Genentech
    Via Business Wire
    FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
    From Genentech
    Via Business Wire
    Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
    Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD. 
    Via Benzinga
    Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
    From Genentech
    Via Business Wire
    Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
    Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. 
    Via Benzinga
    Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants
    Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits. 
    Via Benzinga
    Topics Cannabis
    Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
    Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
    Via Benzinga
    Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint
    The company is also facing off with biosimilars for standard Eylea and competition with Roche. 
    Via Investor's Business Daily
    Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
    Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
    Via Investor's Business Daily
    Topics Artificial Intelligence Government
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.